Overcoming scientific barriers in the transition from to non-animal batch testing of human and veterinary vaccines.
dc.contributor.author | van den Biggelaar, Robin H G A | |
dc.contributor.author | Hoefnagel, Marcel H N | |
dc.contributor.author | Vandebriel, Rob J | |
dc.contributor.author | Sloots, Arjen | |
dc.contributor.author | Hendriksen, Coenraad F M | |
dc.contributor.author | van Eden, Willem | |
dc.contributor.author | Rutten, Victor P M G | |
dc.contributor.author | Jansen, Christine A | |
dc.date.accessioned | 2021-10-12T19:53:55Z | |
dc.date.available | 2021-10-12T19:53:55Z | |
dc.date.issued | 2021-09-22 | |
dc.identifier.pmid | 34550041 | |
dc.identifier.doi | 10.1080/14760584.2021.1977628 | |
dc.identifier.uri | http://hdl.handle.net/10029/625316 | |
dc.description.abstract | Before release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still largely rely on in vivo methods. Improved vaccine production processes, ethical concerns, and suboptimal performance of some in vivo tests have led to the development of in vitro alternatives. | en_US |
dc.language.iso | en | en_US |
dc.subject | 3rs | en_US |
dc.subject | alternatives | en_US |
dc.subject | animal model | en_US |
dc.subject | in vitro | en_US |
dc.subject | potency | en_US |
dc.subject | quality control | en_US |
dc.subject | safety | en_US |
dc.subject | vaccines | en_US |
dc.title | Overcoming scientific barriers in the transition from to non-animal batch testing of human and veterinary vaccines. | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1744-8395 | |
dc.identifier.journal | Expert Rev Vaccines 2021; 20(13):1221-1233 | en_US |
dc.source.journaltitle | Expert review of vaccines | |
dc.source.beginpage | 1 | |
dc.source.endpage | 13 | |
dc.source.country | England |